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Background: Cardiac resynchronization therapy (CRT) has been widely used for the treatment of
refractory heart failure (HF). However, the efﬁcacy of CRT is not well established in class IV HF patients
on inotropic support.
Methods: Twenty-six patients (age 55718 years, 73% men) with inotrope-dependent HF were reviewed
to evaluate the effectiveness of CRT in class IV HF patients on inotropic support.
Results: Intravenous inotropic therapy was administered for 72756 days before CRT and consisted of
dobutamine (n¼24; 3.071.2 μg kg−1 min−1), dopamine (n¼2; 4.572.1 μg kg−1 min−1), and/or milrinone
(n¼16; 0.1270.09 μg kg−1 min−1). CRT did not produce signiﬁcant reverse remodeling in eligible patients
(left ventricular ejection fraction 2377% to 2579%; p¼0.23, left ventricular end-diastolic diameter
7079 mm to 6879 mm; p¼0.14). After CRT device implantation, 13 (50%) patients experienced 1 or more
episodes of ventricular tachyarrhythmia or sudden cardiac death. Twenty (77%) patients survived to
hospital discharge with weaning from inotropic support (70770 days after CRT implantation).
The 1-year survival rate was 81%. However, data from long-term follow-up showed that 68% of the study
patients who attained survival discharge had an HF hospitalization event within the follow-up period.
Conclusion: CRT did not result in signiﬁcant reverse remodeling in patients with inotrope-dependent class IV
end-stage HF. However, it contributed to dramatically improve the cardiovascular outcomes at least in the
short-term period in some patients.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Patients with inotrope-dependent class IV end-stage heart failure
(HF) have an extremely poor prognosis with medical therapy alone
[1]. For these patients, cardiac transplantation or left ventricular
assist device (LVAD) implantation is a suitable option to improve the
morbidity and mortality rates. However, because of poor number of
donors, legal issues, or ﬁnancial cost, these therapies could not be
used widely especially in non-Western countries.
A signiﬁcant proportion of HF patients with depressed left
ventricular ejection fraction (LVEF) has abnormal electrical activa-
tion that is associated with cardiac dyssynchrony. Biventricular
pacing has been shown to improve the prognosis of these
patients [2]. Recent clinical evidences have shown that cardiact Rhythm Society. Published by Els
ka 565-8565, Japan.resynchronization therapy (CRT) has made remarkable progress
for patients with HF [3–5].
According to a previous report [6], even in patients with New
York Heart Association (NYHA) class IV HF, CRT signiﬁcantly
improves mortality and hospitalization rates. However, hemody-
namically unstable severe HF patients who require inotropes are
usually excluded from major CRT trials, and the current guidelines
do not recommend CRT as a therapeutic option for such patients
[7,8]. Accordingly, there are limited data about CRT implantation
in class IV HF patients on continuous inotropic support, and the
efﬁcacy of CRT for such patients is not well established.2. Methods
2.1. Study population
The population of this retrospective review study comprised
consecutive patients implanted with a CRT device between Aprilevier B.V. All rights reserved.
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Center in Japan. We excluded patients who could not be followed-
up for at least 2 years for reasons besides death or LVAD
implantation, in order to evaluate the long-term prognosis. The
indications for CRT implantation in this population were based on
the international standard guidelines [7,8], which include LV
systolic dysfunction (LVEF o35%), advanced HF (NYHA class
42), and wide QRS complex (4120 ms) after optimal medical
therapy. Among our cohort, we identiﬁed 26 consecutive patients
with NYHA class IV HF on inotropic support (age 55718 years,
73% men) who underwent CRT implantation. Clinical character-
istics and evaluation variables, including blood tests, 12-lead
electrocardiogram, and echocardiography, were recorded at base-
line and at all follow-up visits after CRT implantation. This study
complies with the Declaration of Helsinki and was approved by
the local ethics committee.2.2. Deﬁnition of inotrope dependence
We deﬁned inotrope dependence as the inability to stop
or decrease the dose of the inotropes without hypotension,
oliguria (o400 mL/day), and/or hypoxia [9]. We excluded patients
who required perioperative inotropes within 4 weeks owing to
inotrope dependence and a decompensated state of HF. The
inotropes used included dobutamine, dopamine, and milrinone.
All eligible patients were admitted non-electively, required intra-
venous inotropic therapy for hemodynamic maintenance, and
underwent CRT implantation while on inotropic support.Table 1
Baseline characteristics of the inotrope-dependent class IV patients.
Clinical parameters Inotrope-dependent class
IV patients (n¼26)
Age (years)
Male (%) 55718
Ischemic etiology (%) 19 (73%)
Diabetes (%) 4 (15%)
Chronic kidney disease (%) 6 (23%)
CRT-D/CRT-P (%) 12 (48%)2.3. Echocardiographic evaluation
All patients underwent routine echocardiography before and
after CRT device implantation. Standard 2-dimensional echocar-
diography and Doppler imaging were performed by well-trained
echocardiographists and reviewed by cardiologists. LV end-
diastolic diameter (LVDD), LV end-systolic diameter (LVDS), and
LVEF were measured using the modiﬁed biplane Simpson rule [10].
For quantiﬁcation of mitral regurgitation (MR), apical 4-chamber
images were used. MR was characterized as none¼0, mild¼1 (jet
area/left atrium [LA] area o10%), moderate¼2 (jet area/LA area
10–20%), moderate-severe¼3 (jet area/LA area 20–45%), and
severe¼4 (jet area/LA area 445%).SR (%) 20 (77%)/6 (23%)
Permanent AF (%) 16 (62%)
QRS duration (ms) 10 (38%)
History of sustained VT (%) 159738
History of VF (%) 8 (31%)
Echocardiographic parameters 2 (8%)
LVEF (%)
LVDD (mm) 2477
LVDS (mm) 7179
Mitral regurgitation (grade) 62710
Conduction disorders (%) 2.370.9
Left bundle-branch block
Intraventricular conduction delay 11 (42%)
Right bundle-branch block 10 (38%)
Medications (%) 5 (19%)2.4. Device implantation and management
All patients underwent CRT implantation under general
anesthesia and mechanical ventilation. All pacing and deﬁbrillator
systems were implanted transvenously. During the procedure, the
sensing and pacing thresholds were measured.
During follow-up, device interrogation was scheduled, and the
pacing/sensing thresholds and arrhythmic events were checked.
CRT optimization, including adjustment for atrioventricular and
interventricular timing, was performed using echocardiography at
1 month and when necessary after device implantation.ACE inhibitor or ARB 19 (73%)
β-Blocker 23 (88%)
Amiodarone 17 (65%)
Diuretics 26 (100%)
Digoxin 11 (43%)
CRT-D: cardiac resynchronization therapy with deﬁbrillator; CRT-P: cardiac resyn-
chronization therapy pacemaker; SR: sinus rhythm; AF: atrial ﬁbrillation; VT:
ventricular tachycardia; VF: ventricular ﬁbrillation; LVEF: left ventricular ejection
fraction; LVDD: left ventricular end-diastolic diameter; LVDS: left ventricular end-
systolic diameter; ACE: angiotensin-converting enzyme; ARB: angiotensin II recep-
tor blockers.2.5. Clinical response and endpoints
The clinical response to CRT was evaluated at 3 months follow-
up. All adverse cardiac events, including all hospitalizations due to
a cardiac cause, all deaths, and all lethal arrhythmic events were
followed. In addition, the number of survival discharge or in-
hospital deaths after CRT was also identiﬁed. LVAD implantation
was considered as the endpoint in this study.2.6. Statistical analysis
A p-value of o0.05 was considered statistically signiﬁcant.
Continuous variables are expressed as mean7SD. For pairwise
comparisons, a paired t test was used for normally distributed
data. Non-normally distributed data were compared using the
Wilcoxon signed rank test. All tests were 2-sided. The survival
function was computed as the time of implantation to the event.
The observation was censored at the time of the last known
follow-up or at the time of the events. Event-free survival curves
were calculated according to the Kaplan–Meier method. Statistical
analysis was performed using the JMP 10 software.3. Results
3.1. Baseline characteristics
We retrospectively reviewed 26 consecutive inotrope-
dependent class IV patients who underwent CRT at our institution.
The baseline characteristics of the eligible patients are shown in
Table 1. All patients had a depressed LVEF (2377%), wide QRS
complex (159738 ms), and high brain natriuretic peptide (BNP)
level (6087481 pg/mL). Concerning the etiology of the underlying
heart disease, ischemic heart disease occurred in 15% and non-
ischemic heart disease occurred in 85%.
3.2. Inotropic support and mechanical support
Intravenous inotropic therapy was administered for 72756 days
before CRT implantation and consisted of dobutamine (n¼24;
3.071.2 μg kg−1 min−1), dopamine (n¼2; 4.572.1 μg kg−1 min 1),
and/or milrinone (n¼13; 0.1270.09 μg kg−1 min−1). Three patients
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the intravenous inotropic agents were gradually decreased, and 20
of 26 patients (77%) were able to withdraw from inotropic support.
The average time to weaning from inotropic therapy was
70770 days.3.3. Follow-up clinical evaluation
At 3 months follow-up, the symptoms of HF improved in 20
(77%) patients to NYHA class I (n¼1), class II (n¼10), class III
(n¼4), and class IV without inotropic support (n¼5). However,
after CRT implantation, 3 (12%) patients died within 3 months and
3 (12%) patients could not withdraw from inotropic support
(Fig. 1). Concerning echocardiographic changes after 3 months
follow-up, the LV systolic function and LV volumes showed no
signiﬁcant changes after CRT implantation (LVEF at baseline:
2377% vs. at 3 months follow-up: 2579%; p¼0.23, LVDD atNYHA I
1 (4%)
Death
3 (12%) 
NYHA IV
(inotrope-dependent)
3 (12%) 
NYHA IV
5 (19%)
NYHA III
4 (15%)
Inotrope-dependent
class IV patients (N = 26)
NYHA function class (Post-CRT)
3 months
NYHA II
10 (38%)
Fig. 1. Changes of New York Heart Association (NYHA) functional class at 3 months
follow-up. The symptom of heart failure improved in 20 (77%) patients to NYHA
class I (n¼1), class II (n¼10), class III (n¼4), and class IV without inotropic support
(n¼5). However, 3 (12%) patients died within 3 months and 3 (12%) patients could
not withdraw from inotropic support.
Table 2
Changes after CRT in inotrope-dependent class IV patients.
Variables Pre-CRT Post-CRT p Value
LVEF (%) 2377 2579 0.23
LVDD (mm) 7079 6879 0.14
LVDS (mm) 61710 6079 0.18
Mitral regurgitation 2.271.0 1.771.0 0.008
BNP (pg/mL) 6087481 4527391 0.021
Hemoglobin (g/dL) 11.471.8 11.671.8 0.92
Sodium (mEq/L) 134.374.1 135.874.7 0.043
Creatinine (mg/dL) 1.2570.58 1.1670.44 0.84
Total bilirubin (mg/dL) 1.0270.67 0.6870.47 o0.001
CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction;
LVDD: left ventricular end-diastolic diameter; LVDS: left ventricular end-systolic
diameter; BNP: brain natriuretic peptide.baseline: 7079 mm vs. at 3 months follow-up: 6879 mm;
p¼0.14, LVDS at baseline: 61 710 mm vs. at 3 months follow-
up: 6079 mm; p¼0.18); however, the MR signiﬁcantly decreased
(mean grade at baseline: 2.271.0 vs. at 3 months follow-up:
1.771.0, po0.005). Other changes in clinical parameters from
pre-CRT to post-CRT are listed in Table 2. The BNP levels decreased
signiﬁcantly after CRT implantation compared with those before
CRT implantation (pre-CRT: 6087481 pg/mL vs. post-CRT:
4527391 pg/mL, p¼0.021).3.4. Clinical outcomes
During a mean follow-up of 10337742 days, 9 (35%) patients
died within 2 years and 13 (50%) patients experienced 1 or more
episodes of ventricular tachyarrhythmia or sudden cardiac death
after CRT. Among those patients, 20 (77%) survived to hospital
discharge, and the 1-year survival rate was 81%. However, 68% of
the study patients had an episode of HF rehospitalization during
the follow-up period. Only 1 patient had successful cardiac
transplantation, and 6 patients required LVAD implantation.
Fig. 2 shows the event-free survival curve for all-cause death or
LVAD implantation. The 1-year and 2-year survival rates were 81%
and 65%, respectively. Fig. 3 shows the event-free survival curve
for HF rehospitalization among the patients who survived to
hospital discharge after the successful withdrawal of inotropic
support. The 1-year and 2-year event-free survival rates were 65%
and 44%, respectively. Fig. 4 shows the event-free survival curve
for ventricular tachyarrhythmias or sudden cardiac death after
CRT. On the basis of the analysis, lethal ventricular arrhythmias
occurred frequently within 100 days. The event-free rate at 1-year
was 65%.4. Discussion
Our study had 3 major ﬁndings. First, most of the inotrope-
dependent patients can withdraw from inotrope therapy and be
discharged from the hospital after CRT implantation. Second,
concerning echocardiographic parameters, CRT did not result in
signiﬁcant LV reverse remodeling among our study patients at
3 months follow-up. Finally, CRT improved the symptoms and
short-term outcome in patients with inotrope-dependent class IV
end-stage HF.E
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Fig. 2. Cumulative probability of survival for patients with inotrope-dependent
class IV heart failure after cardiac resynchronization therapy (CRT) implantation.
The Kaplan–Meier curve for all-cause mortality in patients with inotrope-depen-
dent class IV heart failure after device implantation indicates that the 1-year and
2-year survival rates were 81% and 65%, respectively.
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Fig. 4. Cumulative free probability of ventricular tachyarrhythmias or sudden
cardiac death in patients with inotrope-dependent class IV heart failure (HF) after
cardiac resynchronization therapy (CRT) implantation. The Kaplan–Meier curve for
ventricular tachyarrhythmias or sudden cardiac death in patients with inotrope-
dependent class IV HF after device implantation shows that lethal ventricular
arrhythmia occurred frequently within 100 days, and the event-free rate at 1 year
was 65%.
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Fig. 3. Cumulative free probability of heart failure (HF) hospitalization in patients
with inotrope-dependent class IV HF after cardiac resynchronization therapy (CRT)
implantation. The Kaplan–Meier curve for HF hospitalization in patients with
inotrope-dependent class IV HF who were discharged after device implantation
shows that the 1-year and 2-year event-free survival rates were 65% and 44%,
respectively.
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patients with end-stage HF. The REMATCH trial reported extre-
mely poor outcomes in the medical therapy—only group in
patients with end-stage HF [1]. In that study, the optimal medical
therapy group included 75% inotrope-dependent HF patients and
the 1-year survival rate was only 25%. In relation to the compar-
ison with LVAD patients, the HeartMate II trial studied the
outcomes in continuous-ﬂow LVAD patients [11]. Even in those
patients, the 1- and 2-year survival rates were 68% and 58%,
respectively. Our patients had similar baseline characteristics
except that most had non-ischemic HF. However, the 1-year
survival rate in our study population after CRT was 81%, which
supports the favorable effects of CRT in patients with inotrope-
dependent HF.
Herweg et al. [9] evaluated the beneﬁt of CRT in 10 consecutive
patients with NYHA class IV HF who were dependent on inotropic
support. Their patients had received inotropic support for
1467258 days, and all patients were alive at the mean follow-
up of 10887284 days after CRT. They also reported an improve-
ment in LVEF (23.574.3% to 32.079.1%; po0.05). Cowburn et al.
[12] identiﬁed 10 patients who required inotropic support andunderwent CRT while being administered with inotropic agents.
All patients were weaned from inotropic agents and survived to
hospital discharge. These reports are congruent with our report
and support the beneﬁcial effects of CRT for patients with
inotrope-dependent HF. However, Adelstein et al. [13] reported
conﬂicting ﬁndings. They divided their cohort of CRT patients into
3 groups according to exposure to intravenous inotropes before
CRT—(1) no inotropes, (2) previous inotrope administration, and
(3) dependent on inotropes—and compared the clinical outcomes.
In their study, 16 inotrope-dependent patients were identiﬁed
and the 1-year survival rate was o20%. In addition, inotrope-
dependent patients exhibited neither functional improvement nor
reverse remodeling in their study. The discrepancy between our
study and their report may be partly explained by the fact that
many of their patients had LVAD implantation and cardiac trans-
plantation. It may be easier to assess LVAD or cardiac transplanta-
tion owing to the differences in social background. Moreover,
most of our patients had non-ischemic cardiomyopathy, and were
generally thought to beneﬁt more from CRT than ischemic
cardiomyopathy patients.
Bhattacharya et al. [14] also reported negative effects of CRT for
patients with HF on inotropes at implantation. They retrospec-
tively analyzed 4700 CRT-deﬁbrillator recipients and categorized
them as never on inotropes (NI group), weaned from inotropes
before implantation, or on inotropes at implantation (II group).
Their control group comprised patients with a standard deﬁbril-
lator. They compared the overall survival and survival free from
heart transplant or LVAD between those 4 groups. On the basis of
their report, the II group patients demonstrated signiﬁcantly
shorter survival than the NI group patients at 12 months (hazard
ratio, 2.95; 95% conﬁdence interval, 1.05–8.35), and CRT may not
have a survival advantage over a standard deﬁbrillator for patients
who had received inotropes before CRT. The propensity score-
adjusted event-free survival rate in II group patients with regard to
LVAD and heart transplantation at 12 months was around 60%, and
the overall survival at 12 months was about 70%. Their survival
rate was much better compared with that in the previously
described reports; however, the authors reported no beneﬁcial
effects of CRT for inotrope-dependent HF patients. Their cohort
was the largest study cohort of CRT patients on inotropic support;
however, the II group was not exactly inotrope-dependent (i.e.,
they simply deﬁned the II group as patients on inotropes at CRT
implantation). Furthermore, the control group of patients with a
standard deﬁbrillator comprised only 3% of NYHA class IV patients,
and these control group patients were thought to have milder HF
than the II group patients. From this point of view, the effective-
ness of CRT in inotrope-dependent HF patients could not be
entirely denied.
4.1. Clinical implications
Previous large CRT trials excluded patients with NYHA class IV
HF on inotropic support. Thus, the clinical evidence associated
with the role of CRT in the management of those patients was
unclear. On the basis of the results of our study, 475% of the
studied patients showed improvement in HF symptoms, and the
1-year survival rate was 480%. The ﬁndings of this study strongly
support the beneﬁcial effects of CRT even in inotrope-dependent
HF patients.
We have shown the event-free survival curve for ventricular
tachyarrhythmias after CRT implantation in this study. The inci-
dence of lethal ventricular arrhythmias was remarkably high
especially within 100 days after CRT implantation. This ﬁnding
may be related to the unstable hemodynamics owing to weaning
from inotropes or the proarrhythmic effects of biventricular pacing
[15–17]. These observations raise the concern that patients with
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early phase after CRT to avoid arrhythmic events.
Concerning the mechanical changes after CRT, the eligible
patients did not show signiﬁcantly increasing LVEF and decreasing
LV volume despite the improving MR at 3 months follow-up. The
discrepancy between prognostic and mechanical improvement
after CRT is probably attributable to the inotropic therapy itself.
Inotropic agents usually emphasize systolic function and the pre-
CRT LVEF could be overestimated. The changes in BNP level, serum
sodium, and total bilirubin in patients after CRT implantation
support the improvement in their hemodynamics. Even if signiﬁ-
cant reverse remodeling was not observed after CRT in this study,
the beneﬁt of CRT for functional improvement could not be
denied. The prognosis of patients with inotrope-dependent class
IV end-stage HF is still very poor; however, in the absence of an
indication for heart transplantation or LVAD as a destination
therapy, CRT is one of the most important therapeutic options
for those patients.
4.2. Study limitations
This study was a single-group, non-randomized, retrospective
review study. Although this study had the largest population
among studies on the effects of CRT in patients with inotrope-
dependent class IV end-stage HF, the number of patients was still
small. Further study with a large sample is needed to conﬁrm the
efﬁcacy of CRT for patients with inotrope-dependent class IV end-
stage HF. In addition, the inﬂuence of underlying comorbidities
could be an important factor for determining prognosis besides
CRT effects alone.5. Conclusions
CRT did not result in signiﬁcant reverse remodeling in patients
with inotrope-dependent class IV end-stage HF. However, it
contributed to dramatically improve the symptoms, hemody-
namics, and cardiovascular outcomes at least in a short-term
period in some patients.Conﬂict of interest
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